Abstract
Adenovirus infections are a frequent and serious complication following allogeneic haematopoietic stem cell transplantation (HSCT). The antiviral drugs cidofovir and ribavirin have been used as first-line therapy for disseminated infections with variable results.
In the present study, in vitro susceptibility to these two drugs was evaluated on HlEp-2 cells in adenovirus reference strains representing serotypes of each of the six species and in clinical isolates. Susceptibility to cidofovir was comparable between species with inhibition of replication of all tested serotypes in a narrow dose range (IC50= 17-81 mu M).
However, susceptibility to ribavirin was highly dependent on the species. Serotypes from species A, B, D, E and IF were all resistant to ribavirin (IC50=396 to > 500 mu M).
Only replication of serotypes from species C was inhibited by ribavirin (IC50(=48-108 mu M). This species-dependent susceptibility of adenovirus to ribavirin was confirmed in clinical isolates.
When tested on other cell lines (PLC, A549 and 293), all species were revealed to be resistant to ribavirin. If our in vitro findings are predictive of virological responses in vivo, these results suggest that ribavirin would not be effective for management of non-C species adenovirus infections after HSCT.